NCT07074834

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina

Effectiveness of Metoprolol Succinate Combined With Trimetazidine in Reducing Inflammatory Biomarkers and Improving Clinical Outcomes in Coronary Heart Disease With Angina Pectoris

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Shiyan City Renmin Hospital · Other Government
• Sex: All
• Age: 46 Years – 76 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, randomized study to evaluate the effectiveness and safety of combining metoprolol succinate with trimetazidine compared to standard therapy for patients with coronary heart disease (CHD) and angina pectoris. The study aims to assess the effects of the combination therapy on inflammatory biomarkers, clinical efficacy, angina symptoms, and left ventricular function over a 3-month treatment-period.

Detailed description

Coronary heart disease (CHD) with angina pectoris is a significant cause of morbidity and mortality. While standard treatments like β-blockers (e.g., metoprolol succinate) are effective, many patients continue to experience symptoms. Inflammation is known to play a crucial role in the pathophysiology of CHD. This study was designed to investigate whether the addition of trimetazidine, a myocardial anti-ischemic agent that improves cellular energy metabolism, to standard metoprolol succinate therapy could offer superior benefits. This prospective study enrolled and randomized 102 patients with CHD and angina into two groups: a control group receiving routine drug therapy and a treatment group receiving routine therapy plus metoprolol succinate and trimetazidine. The primary objective was to compare the therapeutic efficacy, changes in angina attack frequency and severity, improvements in left ventricular function, and reductions in key inflammatory markers (IL-1β, TNF-α, hs-CRP, IL-18) between the two groups after 3 months of treatment. The study aims to provide evidence for this combination therapy as a safe and effective option for managing CHD with angina pectoris.

Conditions

• Coronary Heart Disease (CHD)

Interventions

Type	Name	Description
DRUG	Metoprolol Succinate Sustained-Release Tablets	Oral administration. Dose was 23.75 mg once daily for the first two weeks, then increased to 47.50 mg once daily.
DRUG	Trimetazidine	Oral administration. Dose was one tablet twice daily.
DRUG	Routine Drug Therapy	Included oral nitroglycerin tablets (0.5 mg twice daily), aspirin enteric-coated tablets (0.1 g once daily), and rosuvastatin calcium tablets (10 mg three times daily).

Timeline

• Start date: 2021-02-01
• Primary completion: 2022-09-30
• Completion: 2022-12-31
• First posted: 2025-07-20
• Last updated: 2025-07-20

Locations

1 site across 1 country: China